Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Pioglitazone ameliorates Aß42 deposition in rats with diet-induced insulin resistance associated with AKT/GSK3ß activation.

Authors: Yang, Sisi  Chen, Zhe  Cao, Ming  Li, Renjie  Wang, Zhigang  Zhang, Muxun 
Citation: Yang S, etal., Mol Med Rep. 2017 May;15(5):2588-2594. doi: 10.3892/mmr.2017.6342. Epub 2017 Mar 16.
Pubmed: (View Article at PubMed) PMID:28447730
DOI: Full-text: DOI:10.3892/mmr.2017.6342

Pioglitazone may have potential benefits as an alternative therapeutic treatment for patients with Alzheimer's disease (AD), particularly in individuals that also have comorbid diabetes; however, the mechanisms of action remain unclear. The present study aimed to explore the effects of pioglitazone on amyloid ß, isoform 42 (Aß42) deposition in rats with diet-induced insulin resistance (IR). Diet-induced IR model rats were established in the presence or absence of pioglitazone. Plasma glucose and insulin levels, and cerebrospinal ¿uid insulin levels were measured; in addition, hippocampal tissues were collected for immunohistochemical analysis of Aß42 expression. The levels of insulin-degrading enzyme (IDE) and peroxisome proliferator-activated receptor γ (PPARγ) mRNA and protein expression were analyzed by reverse transcription-quantitative polymerase chain reaction and western blotting, respectively. In addition, the activation of glycogen synthase kinase 3ß (GSK3ß) induced by phosphatidylinositol 3-kinase (PI3K) /protein kinase B (AKT) signaling was detected by western blotting. Results from the present study demonstrated that pioglitazone may enhance peripheral and brain insulin sensitivity in diet-induced IR model rats. Treatment with pioglitazone ameliorated Aß42 deposition in the hippocampus by increasing IDE and PPARγ expression. Notably, activation of the PI3K/AKT/GSK3ß pathway was also demonstrated to serve a role in pioglitazone-induced Aß42 degradation, which was abrogated by the PPARγ antagonist GW9662. Results from the present study indicated that pioglitazone may improve insulin sensitivity and ameliorate Aß42 accumulation in rats with diet-induced IR by regulating AKT/GSK3ß activation, suggesting that pioglitazone may be a promising drug for AD treatment.


Disease Annotations
Objects Annotated

Additional Information

RGD Object Information
RGD ID: 13792793
Created: 2018-09-28
Species: All species
Last Modified: 2018-09-28
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.